Viking Therapeutics Faces Intense Competition in Obesity Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the GLP-1 drug market at nearly $200 billion, highlighting significant opportunities for Viking Therapeutics in this sector.
- Investment Return Analysis: If VK2735 gains approval and captures 1% of the market, Viking's valuation could rise from $4.4 billion to $15 billion, allowing a $1,000 investment to grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Pressure: VK2735 must secure approval by 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have established strong market positions with effective treatments, presenting a high barrier for VK2735 to overcome.
- Clinical Trial Risks: VK2735's injectable form demonstrated a 14.7% weight loss in mid-stage trials, but its phase 3 trials won't conclude until 2027, and oral formulation trials are just beginning, creating uncertainty that could lead to investor losses of 60% to 80%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.480
Low
70.00
Averages
97.00
High
125.00
Current: 37.480
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Faces Intense Competition in Obesity Drug Market
- Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the GLP-1 drug market at nearly $200 billion, highlighting significant opportunities for Viking Therapeutics in this sector.
- Investment Return Analysis: If VK2735 gains approval and captures 1% of the market, Viking's valuation could rise from $4.4 billion to $15 billion, allowing a $1,000 investment to grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Pressure: VK2735 must secure approval by 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have established strong market positions with effective treatments, presenting a high barrier for VK2735 to overcome.
- Clinical Trial Risks: VK2735's injectable form demonstrated a 14.7% weight loss in mid-stage trials, but its phase 3 trials won't conclude until 2027, and oral formulation trials are just beginning, creating uncertainty that could lead to investor losses of 60% to 80%.
See More
Viking Therapeutics Faces Market Challenges Ahead of VK2735 Launch
- Intense Market Competition: Viking Therapeutics' VK2735 is expected to hit the market within two years, yet it faces fierce competition from giants like Eli Lilly and Novo Nordisk, which dominate the obesity drug market, potentially hindering Viking's ability to capture market share.
- Clinical Trial Data: VK2735 demonstrated a weight loss of 14.7% in mid-stage trials, but even with promising data, Viking must exhibit significant advantages in efficacy, pricing, and tolerability to secure even 1% of the market.
- Investment Return Forecast: If VK2735 gains approval and captures 1% of the market, projected annual sales could reach $1.5 billion, leading to a potential company valuation of $15 billion based on a 10x price-to-sales ratio, suggesting a $1,000 investment could grow to $3,400, but dilution from new fundraising could reduce it to $2,500.
- Risk Assessment: In the best-case scenario, a $1,000 investment could grow to $10,000 by 2030, but given market competition and clinical trial uncertainties, the most likely outcome is closer to $2,500, highlighting the high-risk nature of investing in Viking.
See More
Market Outlook for Viking Therapeutics by 2030
- Significant Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the broader GLP-1 market at nearly $200 billion, with Viking's VK2735 potentially capturing 1% of the market, translating to $1.5 billion in annual sales.
- Investment Return Expectations: If VK2735 successfully launches and achieves a price-to-sales ratio of 10, Viking's market cap could rise from $4.4 billion to $15 billion, suggesting that a $1,000 investment could grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Landscape: VK2735 faces fierce competition from Eli Lilly and Novo Nordisk, whose drugs have demonstrated significant weight loss in clinical trials, necessitating VK2735 to offer clear advantages in efficacy, pricing, and tolerability to gain market share.
- Slow Clinical Trial Progress: The phase 3 trial for VK2735's injectable form is not expected to complete until 2027, while oral trials are just beginning; failure to replicate favorable data in larger cohorts could lead to a significant drop in investor confidence, potentially reducing a $1,000 investment to a few hundred dollars.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
Viking Therapeutics Faces Intense Competition in Obesity Drug Market
- Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the GLP-1 drug market at nearly $200 billion, highlighting significant opportunities for Viking Therapeutics in this sector.
- Investment Return Analysis: If VK2735 gains approval and captures 1% of the market, Viking's valuation could rise from $4.4 billion to $15 billion, allowing a $1,000 investment to grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Pressure: VK2735 must secure approval by 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have established strong market positions with effective treatments, presenting a high barrier for VK2735 to overcome.
- Clinical Trial Risks: VK2735's injectable form demonstrated a 14.7% weight loss in mid-stage trials, but its phase 3 trials won't conclude until 2027, and oral formulation trials are just beginning, creating uncertainty that could lead to investor losses of 60% to 80%.
See More
Viking Therapeutics Faces Market Challenges Ahead of VK2735 Launch
- Intense Market Competition: Viking Therapeutics' VK2735 is expected to hit the market within two years, yet it faces fierce competition from giants like Eli Lilly and Novo Nordisk, which dominate the obesity drug market, potentially hindering Viking's ability to capture market share.
- Clinical Trial Data: VK2735 demonstrated a weight loss of 14.7% in mid-stage trials, but even with promising data, Viking must exhibit significant advantages in efficacy, pricing, and tolerability to secure even 1% of the market.
- Investment Return Forecast: If VK2735 gains approval and captures 1% of the market, projected annual sales could reach $1.5 billion, leading to a potential company valuation of $15 billion based on a 10x price-to-sales ratio, suggesting a $1,000 investment could grow to $3,400, but dilution from new fundraising could reduce it to $2,500.
- Risk Assessment: In the best-case scenario, a $1,000 investment could grow to $10,000 by 2030, but given market competition and clinical trial uncertainties, the most likely outcome is closer to $2,500, highlighting the high-risk nature of investing in Viking.
See More
Market Outlook for Viking Therapeutics by 2030
- Significant Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the broader GLP-1 market at nearly $200 billion, with Viking's VK2735 potentially capturing 1% of the market, translating to $1.5 billion in annual sales.
- Investment Return Expectations: If VK2735 successfully launches and achieves a price-to-sales ratio of 10, Viking's market cap could rise from $4.4 billion to $15 billion, suggesting that a $1,000 investment could grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Landscape: VK2735 faces fierce competition from Eli Lilly and Novo Nordisk, whose drugs have demonstrated significant weight loss in clinical trials, necessitating VK2735 to offer clear advantages in efficacy, pricing, and tolerability to gain market share.
- Slow Clinical Trial Progress: The phase 3 trial for VK2735's injectable form is not expected to complete until 2027, while oral trials are just beginning; failure to replicate favorable data in larger cohorts could lead to a significant drop in investor confidence, potentially reducing a $1,000 investment to a few hundred dollars.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
